Warsaw-based healthtech startup Ingenix has raised €9 million in seed funding to redefine how clinical trials are conducted using generative AI. With the pharmaceutical industry spending over $50 billion annually on clinical trials—and facing a staggering 90% failure rate in drug approval—Ingenix is introducing a game-changing co-pilot for clinical development that simulates trials before they ever reach real patients.
The fresh capital injection was led by Inovo.vc, a venture capital firm backing global startups from Central and Eastern Europe. Other participants in the round include pan-European deep tech investor OTB Ventures and the International Finance Corporation (IFC), part of the World Bank Group.
A Next-Gen AI Platform to Cut Costs and Speed Up Drug Development
Ingenix is on a mission to improve patient outcomes and reduce the time and cost of drug development by simulating clinical trial results using its proprietary multimodal, multiscale AI platform. This advanced technology models every layer of clinical research—from molecules and cells to tissues, organisms, and entire populations.
Co-founders Piotr Surma and Adam Dancewicz, both serial AI entrepreneurs, are building on their previous success with Applica, an AI startup focused on large language models (LLMs) that was acquired by Snowflake in 2022.
Speaking on the company’s vision, Surma shared:
“Human biology is incredibly complex, but with the right technology, we can bring predictability to the pharmaceutical industry. Ingenix isn’t just simulating clinical trials—we’re building a tool that could reshape how the entire sector operates.”
Meet the GenAI Co-Pilot for Clinical Trials
At its core, Ingenix is developing an AI co-pilot that supports pharmaceutical companies by offering predictive insights and risk modeling for clinical trial planning. By generating accurate simulations of trial endpoints and potential adverse reactions, the platform enables smarter decision-making long before trials begin.
The system uses a combination of multimodal inputs and multiscale analysis to provide a more comprehensive view of potential trial outcomes. This helps optimize trial design, reduce time-to-market, and ensure greater safety for participants.
Backing from Top Investors in Deep Tech and Digital Health
Inovo.vc’s Principal Krzysztof Przybylak emphasized that backing Ingenix was an easy decision after working closely with the founders for almost a year:
“Few teams globally have the expertise and ambition to solve a challenge this complex. We knew early on that Ingenix stood out.”
Wojtek Walniczek, Partner at OTB Ventures, added:
“Ingenix aligns perfectly with our thesis of investing in bold technologies that can reshape entire sectors. Their AI-powered approach could drastically increase both the speed and accuracy of drug development.”
From a global perspective, the IFC sees Ingenix’s technology as crucial for improving healthcare in emerging markets. Ary Naïm, Country Manager for Poland at the World Bank Group, said:
“We’re proud to support AI-driven healthcare innovation from Poland, especially one with scalable potential in underserved regions. Ingenix fits right into our strategy of advancing digital health through responsible tech.”
Aiming for Global Impact from Central Europe
As AI reshapes industries around the world, Ingenix is positioning itself as a pivotal player in the future of clinical research. Their ability to simulate complex biological processes using generative AI not only enhances R&D efficiency but could ultimately help bring life-saving treatments to market faster and more affordably.
With its experienced founding team, strong investor support, and cutting-edge technology, Ingenix is now primed to lead the next era of AI-driven drug development.
